Acrobiosystems Co Ltd
SZSE:301080

Watchlist Manager
Acrobiosystems Co Ltd Logo
Acrobiosystems Co Ltd
SZSE:301080
Watchlist
Price: 42.77 CNY -6.31% Market Closed
Market Cap: 5.1B CNY
Have any thoughts about
Acrobiosystems Co Ltd?
Write Note

Acrobiosystems Co Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Acrobiosystems Co Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Acrobiosystems Co Ltd
SZSE:301080
Interest Income Expense
ÂĄ69.8m
CAGR 3-Years
N/A
CAGR 5-Years
109%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Interest Income Expense
-ÂĄ59.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Interest Income Expense
ÂĄ217.7m
CAGR 3-Years
N/A
CAGR 5-Years
134%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Interest Income Expense
-ÂĄ8.1m
CAGR 3-Years
N/A
CAGR 5-Years
58%
CAGR 10-Years
9%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Interest Income Expense
-ÂĄ45.8m
CAGR 3-Years
27%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Interest Income Expense
ÂĄ78.6m
CAGR 3-Years
37%
CAGR 5-Years
99%
CAGR 10-Years
N/A
No Stocks Found

Acrobiosystems Co Ltd
Glance View

Market Cap
5.1B CNY
Industry
Biotechnology

ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. The company is headquartered in Beijing, Beijing and currently employs 397 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.

Intrinsic Value
49.48 CNY
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Acrobiosystems Co Ltd's Interest Income Expense?
Interest Income Expense
69.8m CNY

Based on the financial report for Dec 31, 2023, Acrobiosystems Co Ltd's Interest Income Expense amounts to 69.8m CNY.

What is Acrobiosystems Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
109%

Over the last year, the Interest Income Expense growth was -9%.

Back to Top